Emerging Antitumor Activities of the Bitter Melon (Momordica charantia)

Author(s): Evandro Fei Fang*, Lynn Froetscher, Morten Scheibye-Knudsen, Vilhelm A. Bohr, Jack Ho Wong, Tzi Bun Ng*.

Journal Name: Current Protein & Peptide Science

Volume 20 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Bitter melon or bitter gourd (Momordica charantia) is a common vegetable in Asia and it is distinctive for its bitter taste. As an ingredient in folk medicine, research from different laboratories in recent years supports its potential medicinal applications with anti-tumor, anti-diabetic, anti-HIV activities in both in vitro and animal studies. In this short review, we summarize herein the recent progress in the antitumor aspect of bitter melon with a focus on the underlying molecular mechanisms. Further mechanistic studies as well as clinical trials are necessary to further verify its medicinal applications.

Keywords: Momordica charantia, bitter melon, anticancer, apoptosis, DNA damage, medicinal applications.

[1]
Fang, E.F.; Ng, T.B. Chapter 27 Achievements, questions arising and future outlook on the path to discover new medicinal compounds.In: Fang, E.F.; Ng, T.B. (Eds.) Antitumor potential and other emerging medicinal properties of natural compounds; Springer: Dordrecht, 2013.
[2]
Fang, E.F.; Ng, T.B. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim. Biophys. Acta, 2011, 1815, 65-74.
[3]
Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
[4]
Bauer, R.; Guo, D.A.; Hylands, P.; Fan, T.P.; Xu, Q. Chapter 25: The role of the GP-TCM research association to modernization and globalization of traditional Chinese Medicine. In: Fang, E.F.; Ng, T.B. (Eds.) Antitumor potential and other emerging medicinal properties of natural compounds; Springer: Dordrecht, 2013.
[5]
Fang, E.F.; Ng, T.B. Bitter gourd (Momordica charantia) is a cornucopia of health: A review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr. Mol. Med., 2011, 11, 417-436.
[6]
Fang, E.F.; Ng, T.B. Can bitter gourd (Momordica charantia) be a novel therapy for human cancers? Med. Aromat. Plants, 2012, 1, 1-2.
[7]
Zhang, C.Z.; Fang, E.F.; Zhang, H.T.; Liu, L.L.; Yun, J.P. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest. New Drugs, 2015, 33(1), 1-11.
[8]
Pan, W.L.; Wong, J.H.; Fang, E.F.; Chan, Y.S.; Ng, T.B.; Cheung, R.C. Preferential cytotoxicity of the type I ribosome inactivating protein alpha-momorcharin on human nasopharyngeal carcinoma cells under normoxia and hypoxia. Biochem. Pharmacol., 2014, 89, 329-339.
[9]
Fang, E.F.; Zhang, C.Z.; Wong, J.H.; Shen, J.Y.; Li, C.H.; Ng, T.B. The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Lett., 2012, 324, 66-74.
[10]
Fang, E.F.; Zhang, C.Z.; Zhang, L.; Fong, W.P.; Ng, T.B. In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int. J. Biochem. Cell Biol., 2012, 44, 1351-1360.
[11]
Fang, E.F.; Ng, T.B. Chapter 21: The bitter fruit with sweet health benefits: A comprehensive synopsis of recent research progress on medicinal properties of momordica charantia. In: Fang, E.F.; Ng, T.B. (Eds.) Antitumor potential and other emerging medicinal properties of natural compounds; Dordrecht, 2013.
[12]
Wong, C.M.; Yeung, H.W.; Ng, T.B. Screening of Trichosanthes kirilowii, Momordica charantia and Cucurbita maxima (family Cucurbitaceae) for compounds with antilipolytic activity. J. Ethnopharmacol., 1985, 13, 313-321.
[13]
Jilka, C.; Strifler, B.; Fortner, G.W.; Hays, E.F.; Takemoto, D.J. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res., 1983, 43, 5151-5155.
[14]
Ray, R.B.; Raychoudhuri, A.; Steele, R.; Nerurkar, P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res., 2010, 70, 1925-1931.
[15]
Kwatra, D.; Subramaniam, D.; Ramamoorthy, P.; Standing, D.; Moran, E.; Velayutham, R.; Mitra, A.; Umar, S.; Anant, S. Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. Evid. Based Complement. Alternat. Med., 2013, 2013, 702869.
[16]
Kaur, M.; Deep, G.; Jain, A.K.; Raina, K.; Agarwal, C.; Wempe, M.F.; Agarwal, R. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cell. Carcinogenesis, 2013, 34, 1585-1592.
[17]
Somasagara, R.R.; Deep, G.; Shrotriya, S.; Patel, M.; Agarwal, C.; Agarwal, R. Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells. Int. J. Oncol., 2015, 46, 1849-1857.
[18]
Fang, E.F.; Zhang, C.Z.; Ng, T.B.; Wong, J.H.; Pan, W.L.; Ye, X.J.; Chan, Y.S.; Fong, W.P. Momordica charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev. Res. (Phila.), 2012, 5, 109-121.
[19]
Fan, J.M.; Luo, J.; Xu, J.; Zhu, S.; Zhang, Q.; Gao, D.F.; Xu, Y.B.; Zhang, G.P. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. Mol. Biotechnol., 2008, 39, 79-86.
[20]
Lee-Huang, S.; Huang, P.L.; Lee-Huang, P. Chapter 8: The discovery of MAP30 and elucidation of its medicinal activities.In: Fang, E.F.; Ng T.B.; (Eds.)Antitumor potential and other emerging medicinal properties of natural compounds; Dordrecht, 2013.
[21]
Xiong, S.D.; Yu, K.; Liu, X.H.; Yin, L.H.; Kirschenbaum, A.; Yao, S.; Narla, G.; DiFeo, A.; Wu, J.B.; Yuan, Y.; Ho, S.M.; Lam, Y.W.; Levine, A.C. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int. J. Cancer, 2009, 125, 774-782.
[22]
Fang, E.F.; Zhang, C.Z.; Fong, W.P.; Ng, T.B. RNase MC2: A new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis, 2012, 17, 377-387.
[23]
Weng, J.R.; Bai, L.Y.; Chiu, C.F.; Hu, J.L.; Chiu, S.J.; Wu, C.Y. Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor gamma activation. Evid. Based Complement. Alternat. Med., 2013, 2013, 935675.
[24]
Zhang, C.Z.; Fang, E.F.; Zhang, H.T.; Liu, L.L.; Yun, J.P. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest. New Drugs, 2015, 33, 1-11.
[25]
Marino, G.; Niso-Santano, M.; Baehrecke, E.H.; Kroemer, G. Self-consumption: The interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol., 2014, 15, 81-94.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 3
Year: 2019
Page: [296 - 301]
Pages: 6
DOI: 10.2174/1389203719666180622095800
Price: $58

Article Metrics

PDF: 19
HTML: 1